NCT05909852View on ClinicalTrials.gov

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

November 24, 2021

Study Completion Date

November 24, 2021

Conditions
Adalimumab
Interventions
DRUG

ABP 501-HCF

Participants will receive a single-dose SC injection of ABP 501-HCF.

DRUG

ABP 501-LCF

Participants will receive a single-dose SC injection of ABP 501-LCF

Trial Locations (3)

33143

Qps-Mra, Llc, South Miami

84124

Pharmaceutical Research Associates, Inc, Salt Lake City

90630

WCCT Global, Inc, Cypress

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05909852 - A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter